Log In Sign up
The largest database of trusted experimental protocols
> Chemicals & Drugs > Organic Chemical > Org 10172

Org 10172

Org 10172 is a unique chemical compound with potential applications in biomedical research.
This small molecule has been the subject of various studies, exploring its potential therapeutic properties and mechanisms of action.
Leveraging advanced AI-driven comparisons, the PubCompare.ai platform can help researchers identify the best protocols and products for studying Org 10172, enhancing reproducibility and streamlining the research process.
Discover the power of AI-driven protocol optimization and unlock new insights into this fasinating chemical entity.

Most cited protocols related to «Org 10172»

1
Standardized Data Collection Protocol for Ischemic Stroke
Cited 16 times
The baseline data of included patients were collected by trained research coordinators following a standard data collection protocol that was developed by the steering committee. The study investigators and research coordinators were trained before the kick-off meeting. Trained research coordinators at each site identified eligible patients, obtained informed consent, enrolled consecutive patients, and collected data by face-to-face interviews with the patients.
Information including prehospital care, prestroke modified Rankin Scale (mRS), National Institutes of Health Stroke Scale (NIHSS) score, Age, Blood pressure, Clincial features, Duration of symptoms and presence of Diabetes (ABCD2) score was collected through a direct interview by trained research coordinators at admission. Aetiology classification of ischaemic stroke was performed according to the TOAST (Trial of Org 10172 in Acute Stroke Treatment) criteria.15 (link) Other data were extracted from medical records that include patient demographics, medical history, family history, previous medication, physical examination, primary diagnosis, laboratory tests and risk factor assessment. At discharge, the research coordinators extracted the auxiliary examination and recorded standard aetiological evaluation result, medication, vascular related operation and surgical procedures, final diagnosis, NIHSS and mRS score, economic burden, cerebrovascular events during hospitalisation. Details of information collected at admission and discharge are presented in online appendix S2.
An electronic data capture system (EDC) was developed and used for data collection. Each participating hospital site entered data using an electronic signature (unique username and password). Trained research coordinators can store data in Pads and then upload the data later. The system can remind the researchers of patients’ follow-up spot, provide feedback of uploaded data timely and facilitate data quality monitoring. All data elements from each patient were automatically checked for completeness, correct coding, value range and logical error through EDC. All data changes made had an electronic audit trail with electronic signature and date. All laboratory test and auxiliary examination results were uploaded to the EDC as pictures. Considering that researchers had varying levels of comfort with the mobile technology, paper-based case report forms were also offered as a supplement if necessary. Independent data monitoring was also performed through EDC by an independent contract research organisation throughout the study period. All data were de-identified before data analysis. 
Wang Y., Jing J., Meng X., Pan Y., Wang Y., Zhao X., Lin J., Li W., Jiang Y., Li Z., Zhang X., Yang X., Ji R., Wang C., Wang Z., Han X., Wu S., Jia Z., Chen Y, & Li H. (2019). The Third China National Stroke Registry (CNSR-III) for patients with acute ischaemic stroke or transient ischaemic attack: design, rationale and baseline patient characteristics. Stroke and Vascular Neurology, 4(3), 158-164.
Publication 2019
Acute Cerebrovascular Accidents Blood Pressure Blood Vessel Cerebrovascular Accident Conditioning, Psychology Diabetes Mellitus Diagnosis Dietary Supplements Face Financial Stress Health Risk Assessment Operative Surgical Procedures Org 10172 Patient Discharge Patients Pharmaceutical Preparations Physical Examination Stroke, Ischemic TNFSF10 protein, human
2
Acute Ischemic Stroke Evaluation Protocol
Cited 10 times
A standardized case‐report form was used to collect demographics, clinical data, and procedural characteristics. Stroke subtype was classified according to the criteria of the Trial of ORG 10172 in Acute Stroke Treatment.19 Symptomatic intracranial hemorrhage (sICH) was defined as that detected within 72 hours after EVT, according to the criteria of the Heidelberg Bleeding Classification.20 Collateral status was assessed based on digital subtracted angiography using the American Society of Interventional and Therapeutic Neuroradiology/Society of Interventional Radiology grading system, with grade 0 to 1 representing poor collateral status and grade 2 to 4 representing moderate to excellent.21Follow‐up of modified Rankin Scale at 3 months was conducted at each center, either by telephone or outpatient visit. Mortality at 3 months was recorded.
Zhang X., Yuan K., Wang H., Gong P., Jiang T., Xie Y., Sheng L., Liu D., Liu X, & Xu G. (2020). Nomogram to Predict Mortality of Endovascular Thrombectomy for Ischemic Stroke Despite Successful Recanalization. Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease, 9(3), e014899.
Publication 2020
Acute Cerebrovascular Accidents Angiography Cerebrovascular Accident Intracranial Hemorrhage Org 10172 Outpatients Radiotherapy Therapeutics X-Rays, Diagnostic
3
Acute Ischemic Stroke Subtyping and Complex Aortic Plaque
Cited 10 times
Subjects for this study were drawn from consecutive patients with acute ischemic stroke who were registered in the Yonsei Stroke Registry [15 (link)]. The Yonsei Stroke Registry is a prospective hospital-based registry of patients with cerebral infarction or transient ischemic attack within 7 days after symptom onset [16 (link)]. During admission, all patients were evaluated according to the standard stroke evaluation that includes brain imaging (computed tomography and/or magnetic resonance imaging [MRI]), vascular imaging studies (digital subtraction angiography, MR angiography, or computed tomography angiography), plain chest X-ray, 12-lead electrocardiography and cardiac echocardiography including TEE. Stroke subtype was determined according to the Trial of Org 10172 in Acute Stroke Treatment (TOAST) classification [17 (link),18 (link)]. Briefly, large artery atherosclerosis is defined as significant (≥50%) stenosis of the large artery relevant to the acute infarction. The presence of complex aortic plaque (CAP) was considered as one form of large artery atherosclerosis. Cardioembolism is defined as at least one potential cardiac source of embolism based on the TOAST classification. A patient with lacunar infarction should have one of the classic clinical lacunar syndromes and a relevant subcortical hemispheric or brain stem lesion with diameter <1.5 cm [16 (link)]. Besides above method of the TOAST classification, we reclassified the TOAST classification. In that reclassification, CAPs were not considered as large artery atherosclerosis. The Institutional Review Board of Severance Hospital, Yonsei University Health System, approved this study and waived the need for patient informed consent because of the retrospective design and observational nature of the study.
Song T.J., Kim Y.D., Yoo J., Kim J., Chang H.J., Hong G.R., Shim C.Y., Song D., Heo J.H, & Nam H.S. (2016). Association between Aortic Atheroma and Cerebral Small Vessel Disease in Patients with Ischemic Stroke. Journal of Stroke, 18(3), 312-320.
Publication 2016
Acute Cerebrovascular Accidents Acute Ischemic Stroke Angiography Angiography, Digital Subtraction Aorta Arteries Atherosclerosis Blood Vessel Brain Brain Stem Cerebral Infarction Cerebrovascular Accident Computed Tomography Angiography Echocardiography Electrocardiography, 12-Lead Embolism Ethics Committees, Research Heart Infarction Infarction, Lacunar Inpatient Org 10172 Patients Radiography, Thoracic Senile Plaques Stenosis Stroke, Lacunar Transient Ischemic Attack X-Ray Computed Tomography
4
Genetic Analysis of Ischemic Stroke Subtypes
Cited 10 times
The discovery sample consisted of 15 cohorts of patients with ischaemic stroke who were of European ancestry from Europe, North America, and Australia, together with controls of matched ancestry. All studies used a case-control methodology. Most participating studies were cross-sectional, whereas four were in large, prospective, population-based cohorts (table 1).

Description of cohorts used in analysis by study population

Number of casesNumber of CS casesNumber of LVD casesNumber of SVD casesNumber of controlsAncestryStudy designGenotyping
Discovery cohorts
ARIC3859331638803EuropeanPopulation-basedAffymetrix 6.0
ASGC11622404213101244EuropeanCross-sectionalIllumina 610
BRAINS3612912097444EuropeanCross-sectionalIllumina 660
CHS454147..732817EuropeanPopulation-basedIllumina 370
deCODE239139925524026 970EuropeanCross-sectionalIllumina 317/370
FHS17148....4164EuropeanPopulation-basedAffymetrix 550
GEOS448903754498EuropeanCross-sectionalIllumina HumanOmni1
HPS578......468EuropeanCross-sectionalIllumina 610
HVH56688611731290EuropeanCross-sectionalIllumina 370
ISGS/SWISS10702472292012329EuropeanCross-sectionalIllumina 550/610/660
MGH-GASROS51616995381202EuropeanCross-sectionalAffymetrix 6.0
Milano372257465407EuropeanCross-sectionalIllumina 610/660
Rotterdam367......5396EuropeanPopulation-basedIllumina 550
WTCCC2-Munich1174330346106797EuropeanCross-sectionalIllumina 660
WTCCC2-UK23744604984745175EuropeanCross-sectionalIllumina 660
Total (discovery)12 38923652167189462 004......
Replication cohorts
Barcelona439179110150404EuropeanCross-sectionalSequenom
BSS225119390312EuropeanCross-sectionalSequenom
Copenhagen730......1545EuropeanCross-sectionalTaqMan
ESS276402069940EuropeanCross-sectionalTaqMan/Illumina 610
Glasgow67512591150940EuropeanCross-sectionalSequenom/Illumina 610
Go-Darts*737130259..8424EuropeanCross-sectionalAffymetrix 6.0/Illumina Cardio-metabochip
Graz657116108207848EuropeanCross-sectionalSequenom/Illumina 610
Interstroke*872143198238926EuropeanCross-sectionalIllumina Cardio-metabochip
Krakow1235377152171584EuropeanCross-sectionalSequenom
Leuven4581958363391EuropeanCross-sectionalSequenom
Lund4241402194466EuropeanCross-sectionalSequenom
Munster12324785282241053EuropeanCross-sectionalSequenom
Portugal539......507EuropeanCross-sectionalSequenom
RACE (Pakistan)*13222251951891143PakistaniCross-sectionalIllumina 660
SMART623303681956712EuropeanPopulation-basedSequenom
Sweden87615717775742EuropeanCross-sectionalSequenom
VISP*1725......1047EuropeanCross-sectionalIllumina HumanOmni1
WHI*3024231782099EuropeanPopulation-basedIllumina Omni-Quad
Total (replication)13 34723882434199329 083......

CS=cardioembolic stroke. LVD=large-vessel disease. SVD=small-vessel disease. ARIC=The Atherosclerosis Risk in Communities study. ASGC=Australian Stroke Genetics Collabarative. BRAINS=Bio-Repository of DNA in stroke. CHS=Cardiovascular Health Study. FHS=Framingham Heart Study. GEOS=Genetics of Early-Onset Stroke. HPS=Heart Protection Study. HVH=The Heart and Vascular Health Study. ISGS/SWISS=The Ischemic Stroke Genetics Study/Sibling with Ischaemic Stroke Study. MGH-GASROS=The MGH Genes Affecting Stroke Risk and Outcome Study. WTCCC2-Munich=The Wellcome Trust Case-Control Consortium II Munich. WTCCC2-UK=The Wellcome Trust Case-Control Consortium II UK. BSS=Belgium Stroke Study. ESS=Edinburgh Stroke Study. Go-Darts=Genetics of Diabetes Audit and Research in Tayside Study. RACE=Risk Assessment of Cerebrovascular Events Study, Pakistan. SMART=Second Manifestations of ARTerial disease. VISP=The Vitamin Intervention for Stroke Prevention Trial. WHI=The Women's Health Initiative.

Contributed genome-wide data.

Additionally, 18 cohorts were analysed in the replication phase. These cohorts were included for replication only, most did not have GWAS data available; and those with GWAS data were not available at the time of the discovery analysis. 17 of the included cohorts contained individuals of solely European ancestry, and one contained individuals of Pakistani ancestry (table 1). Most cohorts (16) were cross-sectional, whereas two were population-based.
The appendix includes detailed descriptions of the design and clinical characteristics of the participating studies.
Stroke was defined as a typical clinical syndrome with radiological confirmation. Stroke subtyping was done with the Trial of Org 10172 in Acute Stroke Treatment (TOAST) classification system.18 Where subtyping was done, brain CT or MRI was undertaken for more than 95% of cases in all the discovery cohorts.
Participating studies were approved by relevant institutional review boards, and all participants gave written or oral consent for study participation, including genetic research, as approved by the local institutional body.
Traylor M., Farrall M., Holliday E.G., Sudlow C., Hopewell J.C., Cheng Y.C., Fornage M., Ikram M.A., Malik R., Bevan S., Thorsteinsdottir U., Nalls M.A., Longstreth W., Wiggins K.L., Yadav S., Parati E.A., DeStefano A.L., Worrall B.B., Kittner S.J., Khan M.S., Reiner A.P., Helgadottir A., Achterberg S., Fernandez-Cadenas I., Abboud S., Schmidt R., Walters M., Chen W.M., Ringelstein E.B., O'Donnell M., Ho W.K., Pera J., Lemmens R., Norrving B., Higgins P., Benn M., Sale M., Kuhlenbäumer G., Doney A.S., Vicente A.M., Delavaran H., Algra A., Davies G., Oliveira S.A., Palmer C.N., Deary I., Schmidt H., Pandolfo M., Montaner J., Carty C., de Bakker P.I., Kostulas K., Ferro J.M., van Zuydam N.R., Valdimarsson E., Nordestgaard B.G., Lindgren A., Thijs V., Slowik A., Saleheen D., Paré G., Berger K., Thorleifsson G., Hofman A., Mosley T.H., Mitchell B.D., Furie K., Clarke R., Levi C., Seshadri S., Gschwendtner A., Boncoraglio G.B., Sharma P., Bis J.C., Gretarsdottir S., Psaty B.M., Rothwell P.M., Rosand J., Meschia J.F., Stefansson K., Dichgans M, & Markus H.S. (2012). Genetic risk factors for ischaemic stroke and its subtypes (the METASTROKE Collaboration): a meta-analysis of genome-wide association studies. The Lancet. Neurology, 11(11), 951-962.
Full text: Click here
Publication 2012
Acute Cerebrovascular Accidents Arteries Atherosclerosis Blood Vessel Brain Cardioembolic Stroke Cardiovascular System Cerebrovascular Accident Diabetes Mellitus DNA Replication Ethics Committees, Research Europeans Genes Genome Genome-Wide Association Study Health Risk Assessment Heart Human Body Org 10172 Patients Stroke, Ischemic Syndrome Vascular Diseases Vitamins X-Rays, Diagnostic
5
Cerebrovascular Imaging and Outcomes in TIA/Stroke
Cited 9 times
We prospectively studied patients with TIA/ischemic stroke from 2 cohorts: the OXVASC (Oxford Vascular) Study and the University of Hong Kong (HKU). In brief, OXVASC is an ongoing population-based study of all acute vascular events occurring within a population of all 92 728 individuals, irrespective of age, who are registered with 100 general practitioners in 9 general practices of Oxfordshire, United Kingdom.15 (link) The analysis herein includes 1080 consecutive cases of TIA/ischemic stroke recruited from November 1, 2004, to September 30, 2014, who had a cerebral magnetic resonance imaging (MRI). The imaging protocol of OXVASC has been described in detail elsewhere.16 (link) Briefly, from April 1, 2002, to March 31, 2010 (phase 1), MRI and magnetic resonance angiography were done in selected patients when clinically indicated. From April 1, 2010, onward (phase 2), brain MRI and magnetic resonance angiography of intra- and extracranial vessels became the first-line imaging methods.16 (link) A further 1076 consecutive patients who were predominantly Chinese with a diagnosis of acute ischemic stroke who received an MRI scan and magnetic resonance angiography of the intra- and extracranial blood vessels at the HKU MRI Unit were recruited during March 1, 2008, to September 30, 2014.
We collected demographic data, atherosclerotic risk factors, and details of hospitalization of index event during face-to-face interview and cross-referenced these with primary care records and hospital records in both cohorts. Cause of TIA/ischemic stroke was classified according to the modified Trial of ORG 10172 in Acute Stroke Treatment (TOAST) criteria.17 (link)Details of scan parameters are documented in Table I in the online-only Data Supplement. Two neuroradiologists (H.K.F.M. and W.K.) supervised the interpretation of the MRI images. PVSs were defined as small (<3 mm) punctate (if perpendicular to the plane of scan) or linear (if longitudinal to the plane of scan) hyperintensities on T2 images in the BG or CS based on a previously validated scale.18 (link) In patients with asymmetrical number of PVSs, the side with the higher number of PVSs was counted.18 (link) Burden of PVSs was then stratified into 3 groups: <11, 11 to 20, and >20 (frequent–severe).18 (link) Definitions of subcortical and periventricular WMH, microbleeds, and lacunes are provided in the online-only Data Supplement. The intrarater κ for burden of PVS (<11, 11–20, and >20) was 0.86 (BG) and 0.84 (CS) in OXVASC and 0.86 (BG) and 0.72 (CS) in HKU (50 scans in each center). Seventy-five MRI scans from HKU were cross-interpreted by investigators in OXVASC with an interrater κ of 0.64 for both BG and CS-PVSs.
All patients in OXVASC were followed up regularly by a research nurse or physician after 1, 3, 6, 12, 24, 60, and 120 months after the index event. Patients recruited from HKU were followed up by a clinician every 3 to 6 months, or more frequently if clinically indicated. All patients were assessed for recurrent stroke (ischemic and hemorrhagic) and death (vascular and nonvascular; see definitions in the online-only Data Supplement). Where needed, details of clinical outcomes were supplemented by electronic or paper medical records from individual primary care practices, hospitals, and the Deaths General Register Office.
Patients gave written informed consent after an event or assent was obtained from relatives for patients who were unable to provide consent. Both cohorts were approved by the local research ethics committee.
Lau K.K., Li L., Lovelock C.E., Zamboni G., Chan T.T., Chiang M.F., Lo K.T., Küker W., Mak H.K, & Rothwell P.M. (2017). Clinical Correlates, Ethnic Differences, and Prognostic Implications of Perivascular Spaces in Transient Ischemic Attack and Ischemic Stroke. Stroke, 48(6), 1470-1477.
Full text: Click here
Publication 2017
Acute Cerebrovascular Accidents Acute Ischemic Stroke Blood Vessel Brain Cerebrovascular Accident Chinese Diagnosis Ethics Committees, Research Face General Practitioners Hemorrhage Hospitalization Magnetic Resonance Angiography Nurses Org 10172 Patients Physicians Primary Health Care Radionuclide Imaging Stroke, Ischemic

Most recents protocols related to «Org 10172»

1
Serum Bilirubin and Ischemic Stroke Risk
Demographic characteristics, including age and sex, were collected and data concerning a history of atrial fibrillation (AF), diabetes mellitus, hypertension, coronary heart disease (CHD), current cigarette smoking, and current drinking status were obtained to assess stroke risk.
Laboratory tests were performed within 24 h of hospital admission under fasting conditions. Laboratory findings, including a red blood cell (RBC) count, white blood cell (WBC) count, platelet (PLT) count, and hemoglobin (Hb), fasting blood glucose, total bilirubin (TBIL), direct bilirubin (DB), indirect bilirubin (IDB), alanine aminotransferase (ALT), aspartate aminotransferase (AST), alkaline phosphatase (AKP), and γ-glutamyltranspeptidase (γ-GT) levels were obtained for all patients. Trial of ORG 10172 in Acute Stroke Treatment (TOAST) criteria were used to classify the ischemic stroke subtypes [16 (link)]. Furthermore, the administration of anticoagulant and antiplatelet therapies for acute stroke during hospitalization before HT was recorded. Stroke severity was assessed within 24 h of admission by qualified neurologists using the National Institutes of Health Stroke Scale (NIHSS) score. In addition, the modified Rankin Scale (mRS) score was used to assess the neurological function of each patient at admission.
In the analysis, the TBIL level was taken as the main index representing bilirubin. All patients were divided into quartiles according to the distribution of their baseline serum TBIL level to examine whether any enhancement of performance could be quantified while maintaining sufficient statistical power in each category.
Chen J., Chen Y., Lin Y., Long J., Chen Y., He J, & Huang G. (2023). Roles of Bilirubin in Hemorrhagic Transformation of Different Types and Severity. Journal of Clinical Medicine, 12(4), 1471.
Full text: Click here
Publication 2023
Acute Cerebrovascular Accidents Alkaline Phosphatase Anticoagulants Atrial Fibrillation Bilirubin Blood Glucose Cerebrovascular Accident D-Alanine Transaminase Diabetes Mellitus Erythrocyte Count gamma-Glutamyl Transpeptidase Heart Disease, Coronary Hemoglobin High Blood Pressures Hospitalization Leukocyte Count Nervous System Physiological Phenomena Neurologists Org 10172 Patients Platelet Counts, Blood Serum Stroke, Ischemic Transaminase, Serum Glutamic-Oxaloacetic
2
Retrospective Analysis of Symptomatic Intracranial Atherosclerosis
This was a single-centre retrospective cohort study. Retrospective analysis of 256 patients with suspected sICAS who underwent HR-VWI in our hospital between June 2020 and June 2021 was performed. All patients were classified as having a large atherosclerotic stroke of trial of ORG 10172 in acute stroke treatment (TOAST) type or indicated that the ischaemic event was caused by intracranial atherosclerosis. The inclusion criteria were as follows: (1) complete baseline demographic data and atherosclerotic risk factors data; (2) HR-VWI examination was performed within one week of onset, and all culprit vessels had plaque formation. The exclusion criteria were as follows: (1) non-atherosclerotic vascular disease, such as vascular malformation or intracranial aneurysm (n = 9); (2) received endovascular therapy (n = 12); (3) ipsilateral extracranial artery stenosis ≥ 50% (n = 8); (4) combined with potential cardiogenic embolic factors (e.g., atrial fibrillation) (n = 12); and (5) poor image quality (n = 16). A total of 199 patients were included in the study, including 148 with AIS and 51 with TIA. The patient selection strategy is shown in Figure 1. Each patient or their relatives signed the study consent form before inclusion in the study, which was approved by the Ethics Committee of the Second Affiliated Hospital of Nantong University (No. 2016YXJS010).
We collected demographic data and atherosclerotic risk factors from all patients within 24 h of admission. All patients were started on dual antiplatelet treatment with aspirin (150–300 mg/day) and clopidogrel (75 mg/day, first 300 mg) within 24 h after admission, and they adhered well to regular medication during the follow-up period. Outpatient follow-up was performed 3, 6, 9, and 12 months after discharge. Stroke recurrence was defined as the presence of a new acute infarct focus in the same vascular supply area on diffusion-weighted imaging (DWI) (n = 30). When no imaging was available for the suspected recurrent event, the follow-up was based on the characteristics of the new neurological deficit symptoms (National Institute of Health stroke scale (NIHSS) increase > 4 points) and duration (>24 h) to determine the occurrence of the outcome event (n = 11) [11 (link)]. The follow-up time was defined as during the time of diagnosis to the endpoint events or to the most recent follow-up if no event occurred. The “last observation carried for-ward” protocol was followed for incomplete follow-up data.
Ren K., Jiang H., Li T., Qian C., Zhu L, & Wang T. (2023). Correlation of sLOX-1 Levels and MR Characteristics of Culprit Plaques in Intracranial Arteries with Stroke Recurrence. Diagnostics, 13(4), 804.
Full text: Click here
Publication 2023
Acute Cerebrovascular Accidents Arteries Aspirin Atherosclerosis Atrial Fibrillation BLOOD Blood Vessel Cerebrovascular Accident Clopidogrel Dental Plaque Diagnosis Diffusion Ethics Committees, Clinical Infarction Intracranial Aneurysm Intracranial Atherosclerosis Neurologic Symptoms Org 10172 Outpatients Patient Discharge Patients Pharmaceutical Preparations Stenosis Vascular Malformations
3
Serum Biomarker Profiles in Acute Ischemic Stroke
The sera of patients with AIS and transient ischemic attack (TIA), which were collected within 2 weeks after disease onset, were obtained from Chiba Prefectural Sawara Hospital and Chiba Rosai Hospital. The stroke subtypes were determined according to the criteria of the Trial of ORG 10172 in Acute Stroke Treatment classification system (34 (link)), and large-artery atherosclerosis and small-arterial occlusion (lacuna) were included as AIS or ischemic stroke. The sera of patients with DM and AMI were obtained from Chiba University Hospital and Kyoto University Hospital, respectively. The sera of patients with CKD were obtained from the Kumamoto cohort (35 (link), 36 (link)). The Department of Surgery, Toho University Hospital, collected sera from patients with EC, GC, CRC, lung cancer (LC), and mammary cancer (MC; 37 (link)) between June 2010 and February 2016, and all patients were followed up until July 2018 or death. EC was analyzed in 91 cases, GC was analyzed in 57 cases and CRC was analyzed in 113 cases, of which all cases were underwent radical surgery. Patients who underwent neoadjuvant chemotherapy and had a double cancer were excluded from the study. According to the Japanese Classification of Colorectal, Appendiceal, and Anal Carcinoma, 3d English Edition (Secondary Publication; 38 (link)), the numbers of patients with colorectal cancer were as follows: five patients in stage 0, 29 in stage I, 32 in stage II, 31 in stage III, and 16 in stage IV. In addition, the sera of healthy donors (HDs) were selected from people who underwent a medical checkup at Chiba University, Port Square Kashiwado Clinic, and Chiba Prefectural Sawara Hospital. Clinicopathological characteristics and prognoses were obtained retrospectively. Individuals with no history of cancer, autoimmune disease, or cerebrovascular disease and those without any abnormalities on cranial MRI were enrolled as HDs.
Serum samples of AIS, TIA, DM, CKD, and HD were collected at the time of hospital admission. Serum samples of the cancers were collected before treatment. All serum samples were centrifuged at 3,000 g for 10 min, and the supernatants were stored at −80°C until use. To preserve sample integrity, repeated freezing/thawing of serum samples was avoided.
Li S.Y., Yoshida Y., Kubota M., Zhang B.S., Matsutani T., Ito M., Yajima S., Yoshida K., Mine S., Machida T., Hayashi A., Takemoto M., Yokote K., Ohno M., Nishi E., Kitamura K., Kamitsukasa I., Takizawa H., Sata M., Yamagishi K., Iso H., Sawada N., Tsugane S., Iwase K., Shimada H., Iwadate Y, & Hiwasa T. (2023). Utility of atherosclerosis-associated serum antibodies against colony-stimulating factor 2 in predicting the onset of acute ischemic stroke and prognosis of colorectal cancer. Frontiers in Cardiovascular Medicine, 10, 1042272.
Full text: Click here
Publication 2023
Acute Cerebrovascular Accidents Arterial Occlusion Arteries Atherosclerosis Autoimmune Diseases Cancers, Anal Cerebrovascular Accident Cerebrovascular Disorders Colorectal Carcinoma Congenital Abnormality Cranium Donors Japanese Lung Cancer Malignant Neoplasm of Breast Malignant Neoplasms Neoadjuvant Chemotherapy Operative Surgical Procedures Org 10172 Patients Prognosis Serous Cystadenocarcinoma Serum Stroke, Ischemic Transient Ischemic Attack
4
Characteristics and Treatment of Acute Stroke
Demographics, medical history, stroke characteristics, and use of antiplatelet, direct oral anticoagulant (DOAC), or vitamin K antagonist (VKA; dichotomized into <2 and ≥2 international normalized ratio) were registered. Stroke etiology was determined by the treating neurologist with the TOAST (Trial of ORG 10172 in Acute Stroke Treatment) classification.14 (link) Evaluation of cardioembolic sources such as echocardiography was performed in case of cryptogenic stroke or suspected cardioembolic source.
Kauw F., Velthuis B.K., Takx R.A., Guglielmo M., Cramer M.J., van Ommen F., Bos A., Bennink E., Marquering H.A., Kappelle L.J., de Jong H.W, & Dankbaar J.W. (2023). Detection of Cardioembolic Sources With Nongated Cardiac Computed Tomography Angiography in Acute Stroke: Results From the ENCLOSE Study. Stroke, 54(3), 821-830.
Publication 2023
Acute Cerebrovascular Accidents Anticoagulants Cerebrovascular Accident Cryptogenic Ischemic Stroke Echocardiography International Normalized Ratio Neurologists Org 10172 Vitamin K
5
Prescribers' Choice Adherence After Stroke
In 1997, the Sixth Report of the Joint National Committee (JNC) on Prevention, Detection, Evaluation and Treatment of High Blood Pressure15 (link) established recommendations for first-line therapy based on race-ethnicity and medical comorbidities. The term “a compelling medical indication” was first introduced in the JNC6 based on multiple randomized trials that demonstrated benefit of one or more class of drugs based on patients’ medical comorbidities. While stroke was not specifically listed as a compelling indication, the included meta-analysis demonstrated that high dose diuretics and ACEI were preferred for stroke prevention and while beta blockers were potentially harmful. The recommendations for stroke as a compelling indication was include in the JNC Seventh guideline and have been reaffirmed with subsequent iterations of the JNC (Eighth Reports)12 (link)-14 (link), 16 (link), 17 (link), 19 (link) and the 2020 International Society of Hypertension Global Hypertension Practice Guidelines13 (link) with the recommendation for BP medication choice (Prescribers’-Choice Adherence) after stroke specifically incorporated. Based on this body of knowledge, we designed 5 simple hierarchical rules that can be used to determine Prescribers’-Choice Adherence:
This study followed the Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) reporting checklist. We collected baseline demographic information, insurance status, past medical history and other variables of interest including: final clinical diagnosis related to stroke; stroke etiology for acute ischemic stroke based on the Trial of ORG10172 in Acute Stroke Treatment (TOAST) classification25 (link); medication list prior to stroke admission; antihypertensive medications at discharge; discharge disposition; and modified Rankin score(mRS) at discharge;
Perue G.G., Ying H., Bustillo A., Zhou L., Gutierrez C.M., Wang K., Gardener H.E., Krigman J., Jameson A., Foster D., Dong C., Rundek T., Rose D.Z., Romano J.G., Alkhachroum A., Sacco R.L., Asdaghi N, & Koch S. (2023). A 10-year review of antihypertensive prescribing practices after stroke and the associated disparities from the Florida Stroke Registry. medRxiv.
Publication Preprint 2023
Acute Cerebrovascular Accidents Acute Ischemic Stroke Adrenergic beta-Antagonists Antihypertensive Agents BLOOD Cerebrovascular Accident Diagnosis Diuretics Ethnicity High Blood Pressures Human Body Joints Org 10172 Patient Discharge Patients Pharmaceutical Preparations

Top products related to «Org 10172»

1
Vidas troponin 1 ultra by bioMérieux
Sourced in France
The VIDAS Troponin I Ultra is a laboratory diagnostic equipment designed for the quantitative determination of cardiac troponin I in human serum or plasma samples. It is an automated immunoassay system that utilizes enzyme-linked fluorescent assay (ELFA) technology to provide rapid and reliable results.
2
Rt pa by Boehringer Ingelheim
Sourced in Germany
Rt-PA is a laboratory equipment product used in research applications. It is a recombinant tissue plasminogen activator, a protein that plays a role in the breakdown of blood clots. The core function of Rt-PA is to facilitate the conversion of plasminogen to plasmin, which is an enzyme involved in the dissolution of fibrin clots.
3
Au5400 automatic analyzer by Olympus
Sourced in Japan
The AU5400 is an automatic analyzer designed for clinical chemistry and immunoassay testing. It features a high-throughput capacity and advanced analytical capabilities to provide accurate and reliable results. The core function of the AU5400 is to perform automated analysis of various biological samples, such as blood, urine, and other bodily fluids, to aid in the diagnosis and monitoring of medical conditions.
4
Magnetom trio by Siemens
Sourced in Germany, United States, United Kingdom
The Magnetom Trio is a magnetic resonance imaging (MRI) system manufactured by Siemens. It is designed to produce high-quality images of the body's internal structures. The Magnetom Trio uses a powerful superconducting magnet to generate a strong magnetic field, which, in combination with radio waves, allows for the detailed visualization of the body's anatomy and physiology.
5
Spss statistics 22 by IBM
Sourced in United States, Japan, Germany, United Kingdom, Belgium, Austria, Australia, China, Switzerland
SPSS Statistics 22 is a statistical software package developed by IBM. It provides tools for data management, analysis, and presentation. The software includes features for descriptive statistics, regression analysis, and hypothesis testing.
6
Sysmex7000 analyzer by Sysmex
Sourced in Japan
The SYSMEX7000 analyzer is a hematology instrument designed for automated blood cell analysis. It provides accurate and reliable measurements of various blood parameters, including red blood cells, white blood cells, and platelets. The SYSMEX7000 is capable of performing a comprehensive blood count and differential analysis, offering essential data for clinical decision-making.
7
Spss v15 by IBM
Sourced in United States, Japan, Spain
SPSS v15.0 is a statistical software package developed by IBM. It provides data analysis, data management, and data visualization capabilities. The core function of SPSS v15.0 is to assist users in analyzing and interpreting data through various statistical methods and techniques.
8
Xe 2100 by Sysmex
Sourced in Japan, Germany, United Kingdom, United States, Brazil
The XE-2100 is a hematology analyzer designed for automated blood cell analysis. It provides comprehensive analysis of various blood cell types, including red blood cells, white blood cells, and platelets. The XE-2100 is capable of performing a wide range of hematological tests and measurements to support clinical decision-making.
9
Cobase 702 by Roche
Sourced in Germany, Switzerland
The Cobas 702 is an automated chemistry analyzer designed for clinical laboratories. It provides high-throughput testing capabilities for a wide range of clinical chemistry and immunochemistry assays. The Cobas 702 is capable of performing a variety of tests, including but not limited to, the analysis of proteins, enzymes, lipids, and electrolytes.
10
Sas 9 by SAS Institute
Sourced in United States, Austria, Japan, Belgium, United Kingdom, Cameroon, China, Denmark, Canada, Israel, New Caledonia, Germany, Poland, India, France, Ireland, Australia
SAS 9.4 is an integrated software suite for advanced analytics, data management, and business intelligence. It provides a comprehensive platform for data analysis, modeling, and reporting. SAS 9.4 offers a wide range of capabilities, including data manipulation, statistical analysis, predictive modeling, and visual data exploration.

More about "Org 10172"

Org 10172, chemical compound, biomedical research, therapeutic properties, mechanisms of action, PubCompare.ai, AI-driven comparisons, research protocols, VIDAS Troponin I Ultra, Rt-PA, AU5400 automatic analyzer, Magnetom Trio, SPSS Statistics 22, SYSMEX7000 analyzer, SPSS v15.0, XE-2100, Cobase 702, SAS 9.4, protocol optimization, reproducibility, research process, analytical tools, data, insights